

ASX Announcement | 24 July 2023
Althea Group Holdings (ASX:AGH)

Althea CBD12:THC10 approved for reimbursement in Ireland

Highlights:

- The Republic of Ireland's Primary Care Reimbursement Service has approved Althea CBD12:THC10 for reimbursement in Ireland
- Althea CBD12:THC10 to be reimbursed for:
 - Spasticity associated with multiple sclerosis resistant to all standard therapies and interventions
 - Intractable nausea and vomiting associated with chemotherapy, despite the use of standard anti-emetic regimes

24 July 2023: **Althea Group Holdings Limited (ASX:AGH) ('AGH', or 'the Company')**, a global leader in the manufacturing, sales and distribution of cannabis-based medicines and recreational cannabis products, is pleased to announce that Ireland's Primary Care Reimbursement Service ('PCRS') has approved **Althea CBD12:THC10** for reimbursement in Ireland.

Reimbursement approval for spasticity associated with multiple sclerosis and intractable nausea and vomiting associated with chemotherapy

In a follow up to the Company's ASX announcement on 20 May 2022, Althea CBD12:THC10 has now been added to the PCRS in the Republic of Ireland, making it free of charge for Irish patients.

The Rapid Review Submission for Althea CBD12:THC10 cannabis oil (50 ml), as included in Schedule 1 of the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) (Amendment) Regulations 2023, has resulted in the assignment of administrative codes to facilitate access to the product in line with the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019 (as amended) for the specified therapeutic indications below, with an effective date of 1st August 2023:

1. Spasticity associated with multiple sclerosis resistant to all standard therapies and interventions
2. Intractable nausea and vomiting associated with chemotherapy, despite the use of standard anti-emetic regimes

The agreed reimbursement price for Althea CBD12:THC10 (50ml) is €327.89, or approximately AUD\$540.

Multiple sclerosis (MS) is a complex inflammatory disease of the central nervous system (CNS). The onset of the disease is typically between 20 to 40 years of age, and up to 9,000 people live with this chronic condition in Ireland¹.

Approximately 70% to 80% of adults with cancer experience chemotherapy-induced nausea and vomiting (CINV). CINV remains one of the most distressing symptoms associated with cancer therapy and is associated with decreased adherence to chemotherapy.

¹ <https://www.ms-society.ie/sites/default/files/2019-06/MS%20Ireland%20Quality%20of%20Life%20Booklet%20May%202017.pdf>

² <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594936/>



AGH CEO, Joshua Fegan said: “Any receipt of full reimbursement for a medicine in the pharmaceutical industry is a big development, even more so when the medicine is cannabis-based. Our Medical Affairs team worked closely with the Irish regulator over the last year to make the reimbursement for Althea CBD12:THC10 possible, and this is a great result for them, as well as for patients and doctors in Ireland. An application is underway for Althea THC20: CBD1, recently approved for sale in Ireland, to also be added to the Primary Care Reimbursement Service.”

Extraordinary General Meeting (EGM) reminder

AGH would like to remind shareholders of its previously announced EGM (ASX announcement 14 July 2023) which will be held on 17 August 2023, as a virtual meeting starting at 5pm. The Company has commitments from three company Directors, including the Chairman and Chief Executive Officer, to subscribe for shares at \$0.067 per ordinary share raising \$140,000 and is seeking shareholder approval for the issue of the new shares.

The purchase price of \$0.067 per ordinary share, is a 34% premium to the current share price (\$0.05 as at 21 July 2023).

-ENDS-

Authorised by: Robert Meissner, Company Secretary

For further information, please contact:

Althea Group Holdings Ltd

Joshua Fegan

CEO & Managing Director

M: 1300 70 20 20

E: contact@althea.life

Media & Investor Enquiries

Media & Investor Relations

P: +613 9650 5096

E: investors@althea.life

Althea Group Holdings Limited (ASX:AGH)

Althea Group Holdings Ltd ('AGH') is a global leader in the manufacturing, sales and distribution of cannabis-based medicines and recreational cannabis products. AGH services these sectors via two distinct business units. Althea, the company's pharmaceutical business, offers a comprehensive range of cannabis-based medicines which are made available to patients via prescription. Peak Processing Solutions, AGH's recreational cannabis business, produces legal cannabis products purchased by adult consumers in retail stores.

AGH operates in highly regulated and legal cannabis markets across the world with burgeoning operations in Europe, North America, Australia and Africa.

To learn more about Althea Group Holdings, please visit: www.altheagroupholdings.com

For more information on Peak, please visit: www.peakprocessing.com

For more information on Althea, please visit: www.althea.life

